CoChat

Pharmacological interventions for benzodiazepine mono-dependence management in outpatient settings

Denis, Cecile, Fatseas, Melina, Lavie, Estelle, Auriacombe, Marc · 2006 · Cochrane Database of Systematic Reviews
Cited by 122

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

BACKGROUND: The improved safety profile of benzodiazepines compared to barbiturates has contributed to a high rate of prescription since the seventies. Although benzodiazepines are highly effective for some disorders, they are potentially addictive drugs and they can provide reinforcement in some individuals. OBJECTIVES: To evaluate the effectiveness of pharmacological interventions for benzodiazepine mono-dependence. SEARCH STRATEGY: We searched the Cochrane Drugs and Alcohol Group' Register of Trials (October 2004), the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 4, 2004), MEDLINE (January 1966 to October 2004), EMBASE (January 1988 to October 2004), PsycInfo (1985 to October 2004), CINAHL (1982 to October 2004), Pascal, Toxibase, reference lists of articles. SELECTION CRITERIA: Randomized trials of benzodiazepines dependence management regardless of type, dose (daily and total) and duration of benzodiazepine treatment. DATA COLLECTION AND ANALYSIS: Reviewers independently assessed trials for inclusion, rated their methodological quality and extracted data. MAIN RESULTS: Eight trials involving 458 participants were included. The studies included could not be analysed cumulatively because of heterogeneity of inteventions and participants' characteristics. Results support the policy of gradual rather than abrupt withdrawal of benzodiazepine. Progressive withdrawal (over 10 weeks) appeared preferable if compared to abrupt since the number of drop-outs was less important and the procedure judged more favourable by the participants. Short half-life benzodiazepine, associated with higher drop-out rates, did not have higher withdrawal symptoms scores. Switching from short half-life benzodiazepine to long half-life benzodiazepine before gradual taper withdrawal did not receive much support from this review. The role of propanolol in benzodiazepine withdrawal was unclear; adding tricyclic antidepressant (dothiepin) decreased the intensity of withdrawal symptoms but did not increase the rate of benzodiazepine abstinence at the end of the trial. Buspirone and Progesterone failed to suppress any benzodiazepine symptoms. Carbamazepine might have promise as an adjunctive medication for benzodiazepine withdrawal, particularly in patients receiving benzodiazepines in daily dosages of 20 mg/d or more of diazepam (or equivalents). AUTHORS' CONCLUSIONS: The results of this systematic review point to the potential value of carbamazepine as an effective intervention for benzodiazepine gradual taper discontinuation. Carbamazepine has shown rather modest benefit in reducing withdrawal severity, although it did significantly improve drug-free outcome. Larger controlled studies are needed to confirm these benefits, to assess adverse effects and to identify when its clinical use might be most indicated. Other suggested treatment approaches to benzodiazepine discontinuation management should be explored (antidepressants, benzodiazepine receptors modulator).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/14651858.cd005194.pub2This paper is marked retracted.

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 37

  1. Hallström, 1988, The treatment of tranquillizer dependence by propanolol, Postgraduate Medical Journal, 64, 40
  2. Lemoine, 1997, Withdrawal of long-term administered lorazepam using 6 different plans. A placebo controlled study., Encéphale, 23, 290
  3. Schweizer, 1991, Carbamazepin treatment in patients discontinuing long-term benzodiazepine therapy. effects on withdrawal severity and outcome, Archives of General Psychiatry, 48, 448, 10.1001/archpsyc.1991.01810290060012 · DOI · Paper page
  4. Schweizer, 1995, Progesterone co-administration in patients discontinuing long-term benzodiazepine therapy: effects on withdrawal severity and taper outcome, Psychopharmacology, 117, 424, 10.1007/BF02246214 · DOI
  5. Tyrer, 1996, A controlled trial of dothiepin and placebo in treating benzodiazepine withdrawal symptoms, British Journal of Psychiatry, 168, 457, 10.1192/bjp.168.4.457 · DOI
  6. Busto, 1989, A clinical scale to assess benzodiazepine withdrawal, Journal of Clinical Psychopharmacology, 9, 412, 10.1097/00004714-198912000-00005 · DOI · Paper page
  7. Busto, 1994, Pharmacologic effects and abuse liability of bretazenil, diazepam, and alprazolam in humans, Clinical Pharmacology and Therapeutics, 55, 451, 10.1038/clpt.1994.55 · DOI · Paper page
  8. Busto, 1998, Safety of ipsapirone treatment compared with lorazepam: discontinuation effects, Journal of Psychiatry and Neuroscience, 23, 35
  9. Gerra, 1993, Effectiveness of flumazenil (Ro 15-1788) in the treatment of benzodiazepine withdrawal, Current Therapeutic Research, 54, 580, 10.1016/S0011-393X(05)80679-4 · DOI
  10. Goodman, 1986, Ineffectiveness of clonidine in the treatment of the benzodiazepine withdrawal syndrome: report of three cases, American Journal of Psychiatry, 143, 900, 10.1176/ajp.143.7.900 · DOI · Paper page
  11. Hayward, 1996, Changes in "withdrawal symptoms" following discontinuation of low-dose diazepam, Psychopharmacology, 125, 392, 10.1007/BF02246023 · DOI
  12. Lader, 1993, A comparison of alpidem and placebo in relieving benzodiazepine withdrawal symptoms, International Clinical Psychopharmacology, 8, 31, 10.1097/00004850-199300810-00005 · DOI · Paper page
  13. Lilja, 2001, Evaluation of programs for the treatment of benzodiazepine dependency, Substance Use and Misuse, 36, 1213, 10.1081/JA-100106224 · DOI
  14. McGregor, 2003, In-patient benzodiazepine withdrawal: comparison of fixed and syptom- triggered taper methods, Drug and Alcohol Review, 22, 175, 10.1080/09595230100100615 · DOI · Paper page
  15. Romach, 1998, A controlled trial of ondansetron, a 5-HT3 antagonist, in benzodiazepine discontinuation, Journal of Clinical Psychopharmacology, 18, 121, 10.1097/00004714-199804000-00004 · DOI
  16. Sanchez-Craig, 1987, Cognitive-behavioural treatment for benzodiazepine dependence: a comparison of gradual versus abrupt cessation of drug intake, British Journal of Addiction, 82, 1313, 10.1111/j.1360-0443.1987.tb00434.x · DOI · Paper page
  17. Saxon, 2001, Gender-related differences in response to placebo in benzodiazepine withdrawal: a single-blind pilot study, Psychopharmacologia, 153, 231, 10.1007/s002130000574 · DOI
  18. Saxon, 1997, Effects of flumazenil in the treatment of benzodiazepine withdrawal: a double-blind pilot study, Psychopharmacology, 131, 153, 10.1007/s002130050278 · DOI
  19. Schweizer, 1986, Failure of buspirone to manage benzodiazepine withdrawal, American Journal of Psychiatry, 143, 1590, 10.1176/ajp.143.12.1590 · DOI · Paper page
  20. Tyrer, 1985, Psychological treatment for benzodiazepine dependence, Lancet, 1, 1042, 10.1016/S0140-6736(85)91638-1 · DOI
  21. Voderhorlzer, 2001, A double-blind, randomized and placebo-controlled study on the polysomnographic withdrawal effects of zopiclone, zolpidem and triazolam in healthy subjects, European Archives of Psychiatry and Clinical Neurosciences, 251, 117, 10.1007/s004060170045 · DOI
  22. Vorma, 2002, Treatment of out-patients with complicated benzodiazepine dependence: comparison of two approaches, Addiction, 97, 851, 10.1046/j.1360-0443.2002.00129.x · DOI · Paper page
  23. Voshaar, 2003, Tapering off long-term benzodiazepine use with or without group cognitive-behavioural therapy: three-condition, randomised controlled trial, British Journal of Psychiatry, 182, 498, 10.1192/bjp.182.6.498 · DOI · Paper page
  24. Rickels, 1999, Trazodone and valproate in patients discontinuing long-term benzodiazepine therapy: effects on withdrawal symptoms and taper outcome, Psychopharmacology, 141, 1, 10.1007/s002130050798 · DOI
  25. Saul, 1989, A randomised, multicentre, double-blind, comparison of atenolol and placebo in the control of benzodiazepine withdrawal symptoms, Acta Therapeutica, 15, 117
  26. Bleich, 2002, Benzodiazepine abuse in a methadone maintenance treatment clinic in Isrrael: characteristics and a pharmacotherapeutic approach, Isr J Psychiatry Relat Sci, 39, 104
  27. Wet, 2004, Benzodiazepine co-dependence exacerbates the opiate withdrawal syndrome, Drug and Alcohol Dependence, 76, 31, 10.1016/j.drugalcdep.2004.04.002 · DOI
  28. 1994, Diagnostical and Statistical Manual of Mental Disorders
  29. Kan, 1997, High prevalence of benzodiazepine dependence in out-patient users, based on the DSM-III-R and ICD-10 criteria, Acta Psychiatrica Scandinavica, 96, 85, 10.1111/j.1600-0447.1997.tb09911.x · DOI · Paper page
  30. Kan, 1998, An evaluation of DSM-III-R and ICD-10 benzodiazepine dependence criteria using Rasch modelling, Addiction, 93, 349, 10.1046/j.1360-0443.1998.9333494.x · DOI
  31. Lader, 1991, Benzodiazepine problems, British Journal of Addiction, 86, 823, 10.1111/j.1360-0443.1991.tb01831.x · DOI · Paper page
  32. Lennane, 1986, Treatment of benzodiazepine dependence, Medical Journal of Australia, 144, 594, 10.5694/j.1326-5377.1986.tb112319.x · DOI
  33. Martin, 1982, Diazepam and pentobarbital dependence in the rat, Life Science, 31, 721, 10.1016/0024-3205(82)90697-X · DOI
  34. Moher, 1995, Meta-analysis of randomized controlled trials. A concern for standards, JAMA, 274, 1962, 10.1001/jama.1995.03530240072044 · doi:10.1001/jama.1995.03530240072044 · Paper page
  35. Rickels, 1988, Long-term treatment of anxiety and risk of withdrawal. Prospective comparison of clorazepate and buspirone, Archives of General Psychiatry, 45, 444, 10.1001/archpsyc.1988.01800290060008 · DOI · Paper page
  36. Salzman, 1991, Long-term therapeutic use of benzodiazepines. II. Effects of gradual taper, American Journal of Psychiatry, 148, 151
  37. Winokur, 1980, Withdrawal reaction from long-term, low-dosage administration of diazepam. A double-blind, placebo-controlled case study, Archives of General Psychiatry, 37, 101, 10.1001/archpsyc.1980.01780140103012 · DOI · Paper page

Cited by

See all 122

Metadata

Authors
Denis, C., Fatseas, M., Lavie, E., & Auriacombe, M.
Venue
Cochrane Database of Systematic Reviews
Published
2006-07-19
Issue
3
Pages
CD005194-CD005194
ISSN
1361-6137 (ISSN-L)
OpenAlex
W635630645
Cited by
122
References
16
Type
reference entry
Language
en
Status
Retracted
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.